Nuvation Bio Inc. (NYSE:NUVB) Reports Consistent IBTROZI Efficacy Across ROS1+ NSCLC Subgroups
Nuvation Bio announced new pooled TRUST-I/II analyses showing IBTROZI (taletrectinib) efficacy durable and consistent regardless of prior chemotherapy or ROS1 fusion partner in advanced ROS1+ NSCLC, with safety in line with prior reports.Material DetailsContext by AI AnalystThis is a mid-cycle rein…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.